Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Study Details
Study Description
Brief Summary
This phase II trial studies how well nivolumab works in treating patients with peripheral T-cell lymphoma that has come back after a period of improvement or that does not respond to treatment. Monoclonal antibodies, such as nivolumab, may block cancer growth in different ways by targeting certain cells.
Detailed Description
PRIMARY OBJECTIVES:
- To assess the clinical benefit of nivolumab in T-cell lymphomas, as measured by objective response rate (ORR) within 12 cycles according to the Lugano Classification Response Criteria (2014).
SECONDARY OBJECTIVES:
- To assess safety and tolerability of the regimen in this patient population. II. To assess progression-free survival (PFS). III. To assess duration of response (DOR). IV. To assess overall survival (OS).
TERTIARY OBJECTIVES:
-
To evaluate T-cell/cytokine profile in the peripheral blood - peripheral blood specimens will be used to assess T-cell activation and cytokine up regulation as measures of treatment effect.
-
To evaluate intratumoral biomarkers- intratumoral cell populations and distribution, genetic variability, mutational burden and T-cell activation will be evaluated to identify potential biomarkers that correlate with response to therapy.
-
To assess the potential association between PD-L1/PD-1/PD-L2 expression on tumor and T-cells and/or PD-L1 soluble levels in plasma with clinical efficacy of PD-1 blockade.
OUTLINE:
Patients receive nivolumab intravenously (IV) over 60 minutes on day 1. Treatment repeats every 14 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease, complete response, or partial response receive nivolumab IV over 60 minutes on day 1 of course 9. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 35 days, 100-120 days, 230-250 days, and 330-390 days.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Treatment (nivolumab) Patients receive nivolumab IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease, complete response, or partial response receive nivolumab IV over 60 minutes on day 1 of course 9. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. |
Other: Laboratory Biomarker Analysis
Correlative studies
Biological: Nivolumab
Given IV
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Response Rate for Participants Who Achieve a CR or PR [CT-based Response] [Up to 390 days]
The response rate for participants who achieve a CR or PR is defined as the percentage of participants who achieve a CR or PR assessed according to the revised Lugano Classification Response criteria. Complete response (CR): target nodes/nodal masses must regress to <=1.5 cm in longest transverse diameter (LDi). Partial response (PR): >= 50% decrease in sum of the product of the diameters (SPD) of up to 6 target measurable nodes and extranodal sites.
Secondary Outcome Measures
- Response Rate for Participants Who Achieve a CMR or PMR [PET-CT-based Response] [Up to 390 days]
The response rate for participants who achieve a CMR or PMR is defined as the percentage of participants who achieve a CMR or PMR assessed according to the revised Lugano Classification Response criteria. Complete metabolic response (CMR): Score 1, 2, or 3 with/without a residual mass using the Lugano 5-Point Scale (5-PS). Partial metabolic response (PMR): Score 4 or 5 with reduced update from baseline. The Lugano 5-PS is a scale used for initial staging and assessment of treatment response in Hodgkin lymphoma (HL) and certain types of non-Hodgkin lymphomas (NHL). The scale ranges from 1 to 5, where 1 is best and 5 is the worst. Each FDG-avid (or previously FDG-avid) lesion is rated independently: 1. no uptake or no residual uptake 2. slight uptake, but equal to or below blood pool 3. uptake above mediastinal, but below or equal to uptake in the liver 4. uptake slightly to moderately higher than liver 5. markedly increased uptake or any new lesion (on response evaluation)
- Duration of Response (DOR) [Up to 390 days]
The distribution of duration of response (CR or PR) will be estimated using the method of Kaplan-Meier. Complete response (CR): target nodes/nodal masses must regress to <=1.5 cm in longest transverse diameter (LDi). Partial response (PR): >= 50% decrease in sum of the product of the diameters (SPD) of up to 6 target measurable nodes and extranodal sites.
- Progression-Free Survival (PFS) [The time from registration to relapse or death due to any cause, an average of 2 years]
The distribution of progression-free survival will be estimated using the method of Kaplan-Meier. In addition, the progression-free survival rate will be reported. progressive disease (PD): a Lugano score of 4 to 5 with increasing intensity compared to baseline or any interim scan and/or any new FDG-avid focus consistent with malignant lymphoma.The Lugano 5-PS is a scale used for initial staging and assessment of treatment response in Hodgkin lymphoma (HL) and certain types of non-Hodgkin lymphomas (NHL). The scale ranges from 1 to 5, where 1 is best and 5 is the worst. Each FDG-avid (or previously FDG-avid) lesion is rated independently: 1. no uptake or no residual uptake 2. slight uptake, but equal to or below blood pool 3. uptake above mediastinal, but below or equal to uptake in the liver 4. uptake slightly to moderately higher than liver 5. markedly increased uptake or any new lesion (on response evaluation)
- Overall Survival (OS) [The time from registration to death due to any cause, assessed up to 2 years]
The distribution of survival time will be estimated using the method of Kaplan-Meier.
- Number of Participants Who Experienced at Least One Grade 3 or Higher Adverse Events [Up to 390 days]
The number of participants who experienced at least one grade 3 or higher adverse events are summarized below.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Relapsed or refractory T-cell lymphoma (TCL) biopsy-proven =< 6 months prior to registration, including the following subtypes:
-
Peripheral T-cell lymphoma, not otherwise specified
-
Anaplastic large cell lymphoma, anaplastic lymphoma kinase (ALK) negative, primary systemic type
-
Angioimmunoblastic T-cell lymphoma
-
Extranodal natural killer (NK)/T-cell lymphoma, nasal type
-
Adult T-cell lymphoma/leukemia (human T-lymphotropic virus 1 [HTLV1]+)
-
Blastic NK-cell lymphoma
-
Enteropathy-associated T-cell lymphoma
-
Hepatosplenic gamma delta T-cell lymphoma
-
Transformed mycosis fungoides
-
T/NK-cell lymphoma, unclassifiable
-
Measurable disease: subjects must have at least one lesion that is > 15mm (1.5 cm) in the longest diameter on cross-sectional imaging and measureable in two perpendicular dimensions per computed tomography (spiral CT) or magnetic resonance imaging (MRI)
-
After failure of allogeneic stem cell transplant (ASCT) or after failure of frontline therapy in subjects who declined or are not ASCT candidates
-
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
-
White blood cell (WBC) >= 3000/mm^3
-
Absolute neutrophil count (ANC) >= 1500/mm^3
-
Platelet count >= 100,000/mm^3
-
Hemoglobin > 9.0 g/dL
-
Total bilirubin =< 1.5 x upper limit of normal (ULN) unless elevation due to Gilbert's Syndrome
-
Aspartate transaminase (AST) =< 2.5 x ULN
-
Creatinine =< 2.0 mg/dL
-
Calculated creatinine clearance must be >= 45 ml/min using the Cockcroft-Gault formula
-
Negative serum or urine pregnancy test done =< 7 days prior to registration, for persons of childbearing potential only Note: Persons of child-bearing potential (POCBP) must use appropriate method(s) of contraception; POCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug; men who are sexually active with POCBP must use any contraceptive method with a failure rate of less than 1% per year; men receiving nivolumab and who are sexually active with POCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; persons who are not of childbearing potential (ie, who are postmenopausal or surgically sterile) as well as azoospermic men do not require contraception; should a person become pregnant or suspect being pregnant while participating in this study, the person should inform the treating physician immediately
-
Provide written informed consent
-
Willing to return to enrolling institution for follow-up during the Active Monitoring phase of the study
-
Willing to provide tissue and blood samples for correlative research purposes
Exclusion Criteria:
-
All primary cutaneous T-cell lymphomas
-
Any of the following:
-
Pregnant women
-
Nursing women
-
Men or women of childbearing potential who are unwilling to employ adequate contraception
-
Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
-
Active, known or suspected autoimmune disease Note: subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment
-
Use of systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications < 14 days of registration Note: inhaled or topical steroids are permitted; > 10 mg daily prednisone equivalents are permitted only in adrenal insufficiency in the absence of active autoimmune disease
-
Prohibited treatments and or therapies
-
Autologous stem cell transplant (ASCT) =< 12 weeks prior to first dose of the study drug
-
Prior treatments (window prior to registration):
-
Chemotherapy =< 2 weeks
-
Nitrosureas =< 6 weeks
-
Therapeutic anticancer antibodies =< 4 weeks
-
Radio- or toxin immunoconjugates =< 10 weeks
-
Radiation therapy =< 3 weeks
-
Or major surgery =< 2 weeks
-
Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways
-
Prior allogeneic stem cell transplant (SCT)
-
Chest radiation =< 24 weeks prior to registration
-
Immunocompromised patients, patients with known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) and currently receiving antiretroviral therapy, active hepatitis B virus surface antigen (HBV sAg+), active hepatitis C (if Ab+ then PCR+) indicating acute or chronic infection
-
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
-
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
-
Other active malignancy =< 3 years prior to registration EXCEPTIONS: non-melanotic skin cancer or carcinoma-in-situ of the cervix NOTE: if there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer
-
Active central nervous system (CNS) involvement or leptomeningeal involvement
-
History of pancreatitis
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Mayo Clinic | Rochester | Minnesota | United States | 55905 |
Sponsors and Collaborators
- Mayo Clinic
- National Cancer Institute (NCI)
Investigators
- Principal Investigator: Stephen Ansell, Mayo Clinic
Study Documents (Full-Text)
More Information
Publications
None provided.- MC1681
- NCI-2017-00307
- MC1681
- P30CA015083
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Treatment (Nivolumab) |
|---|---|
| Arm/Group Description | Patients receive 240 mg nivolumab IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease, complete response, or partial response receive 480 mg nivolumab IV over 60 minutes on day 1 of cycle 9. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. |
| Period Title: Overall Study | |
| STARTED | 12 |
| COMPLETED | 12 |
| NOT COMPLETED | 0 |
Baseline Characteristics
| Arm/Group Title | Treatment (Nivolumab) |
|---|---|
| Arm/Group Description | Patients receive 240 mg nivolumab IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease, complete response, or partial response receive 480 mg nivolumab IV over 60 minutes on day 1 of cycle 9. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. |
| Overall Participants | 12 |
| Age (years) [Median (Full Range) ] | |
| Median (Full Range) [years] |
65
|
| Sex: Female, Male (Count of Participants) | |
| Female |
6
50%
|
| Male |
6
50%
|
| Race (NIH/OMB) (Count of Participants) | |
| American Indian or Alaska Native |
0
0%
|
| Asian |
0
0%
|
| Native Hawaiian or Other Pacific Islander |
0
0%
|
| Black or African American |
1
8.3%
|
| White |
11
91.7%
|
| More than one race |
0
0%
|
| Unknown or Not Reported |
0
0%
|
| ECOG Performance Score (Count of Participants) | |
| 0 |
7
58.3%
|
| 1 |
4
33.3%
|
| 2 |
1
8.3%
|
Outcome Measures
| Title | Response Rate for Participants Who Achieve a CR or PR [CT-based Response] |
|---|---|
| Description | The response rate for participants who achieve a CR or PR is defined as the percentage of participants who achieve a CR or PR assessed according to the revised Lugano Classification Response criteria. Complete response (CR): target nodes/nodal masses must regress to <=1.5 cm in longest transverse diameter (LDi). Partial response (PR): >= 50% decrease in sum of the product of the diameters (SPD) of up to 6 target measurable nodes and extranodal sites. |
| Time Frame | Up to 390 days |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Treatment (Nivolumab) |
|---|---|
| Arm/Group Description | Patients receive 240 mg nivolumab IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease, complete response, or partial response receive 480 mg nivolumab IV over 60 minutes on day 1 of cycle 9. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. |
| Measure Participants | 12 |
| Number (95% Confidence Interval) [percentage of participants] |
33.3
277.5%
|
| Title | Response Rate for Participants Who Achieve a CMR or PMR [PET-CT-based Response] |
|---|---|
| Description | The response rate for participants who achieve a CMR or PMR is defined as the percentage of participants who achieve a CMR or PMR assessed according to the revised Lugano Classification Response criteria. Complete metabolic response (CMR): Score 1, 2, or 3 with/without a residual mass using the Lugano 5-Point Scale (5-PS). Partial metabolic response (PMR): Score 4 or 5 with reduced update from baseline. The Lugano 5-PS is a scale used for initial staging and assessment of treatment response in Hodgkin lymphoma (HL) and certain types of non-Hodgkin lymphomas (NHL). The scale ranges from 1 to 5, where 1 is best and 5 is the worst. Each FDG-avid (or previously FDG-avid) lesion is rated independently: 1. no uptake or no residual uptake 2. slight uptake, but equal to or below blood pool 3. uptake above mediastinal, but below or equal to uptake in the liver 4. uptake slightly to moderately higher than liver 5. markedly increased uptake or any new lesion (on response evaluation) |
| Time Frame | Up to 390 days |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Treatment (Nivolumab) |
|---|---|
| Arm/Group Description | Patients receive 240 mg nivolumab IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease, complete response, or partial response receive 480 mg nivolumab IV over 60 minutes on day 1 of cycle 9. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. |
| Measure Participants | 12 |
| Number (95% Confidence Interval) [percentage of participants] |
33.3
277.5%
|
| Title | Duration of Response (DOR) |
|---|---|
| Description | The distribution of duration of response (CR or PR) will be estimated using the method of Kaplan-Meier. Complete response (CR): target nodes/nodal masses must regress to <=1.5 cm in longest transverse diameter (LDi). Partial response (PR): >= 50% decrease in sum of the product of the diameters (SPD) of up to 6 target measurable nodes and extranodal sites. |
| Time Frame | Up to 390 days |
Outcome Measure Data
| Analysis Population Description |
|---|
| Participants who achieved a response are included in this analysis. |
| Arm/Group Title | Treatment (Nivolumab) |
|---|---|
| Arm/Group Description | Patients receive 240 mg nivolumab IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease, complete response, or partial response receive 480 mg nivolumab IV over 60 minutes on day 1 of cycle 9. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. |
| Measure Participants | 4 |
| Median (95% Confidence Interval) [months] |
3.6
|
| Title | Progression-Free Survival (PFS) |
|---|---|
| Description | The distribution of progression-free survival will be estimated using the method of Kaplan-Meier. In addition, the progression-free survival rate will be reported. progressive disease (PD): a Lugano score of 4 to 5 with increasing intensity compared to baseline or any interim scan and/or any new FDG-avid focus consistent with malignant lymphoma.The Lugano 5-PS is a scale used for initial staging and assessment of treatment response in Hodgkin lymphoma (HL) and certain types of non-Hodgkin lymphomas (NHL). The scale ranges from 1 to 5, where 1 is best and 5 is the worst. Each FDG-avid (or previously FDG-avid) lesion is rated independently: 1. no uptake or no residual uptake 2. slight uptake, but equal to or below blood pool 3. uptake above mediastinal, but below or equal to uptake in the liver 4. uptake slightly to moderately higher than liver 5. markedly increased uptake or any new lesion (on response evaluation) |
| Time Frame | The time from registration to relapse or death due to any cause, an average of 2 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Treatment (Nivolumab) |
|---|---|
| Arm/Group Description | Patients receive 240 mg nivolumab IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease, complete response, or partial response receive 480 mg nivolumab IV over 60 minutes on day 1 of cycle 9. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. |
| Measure Participants | 12 |
| Median (95% Confidence Interval) [months] |
1.9
|
| Title | Overall Survival (OS) |
|---|---|
| Description | The distribution of survival time will be estimated using the method of Kaplan-Meier. |
| Time Frame | The time from registration to death due to any cause, assessed up to 2 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Treatment (Nivolumab) |
|---|---|
| Arm/Group Description | Patients receive 240 mg nivolumab IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease, complete response, or partial response receive 480 mg nivolumab IV over 60 minutes on day 1 of cycle 9. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. |
| Measure Participants | 12 |
| Median (95% Confidence Interval) [months] |
7.9
|
| Title | Number of Participants Who Experienced at Least One Grade 3 or Higher Adverse Events |
|---|---|
| Description | The number of participants who experienced at least one grade 3 or higher adverse events are summarized below. |
| Time Frame | Up to 390 days |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Treatment (Nivolumab) |
|---|---|
| Arm/Group Description | Patients receive 240 mg nivolumab IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease, complete response, or partial response receive 480 mg nivolumab IV over 60 minutes on day 1 of cycle 9. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. |
| Measure Participants | 12 |
| Count of Participants [Participants] |
6
50%
|
Adverse Events
| Time Frame | Up to 390 days | |
|---|---|---|
| Adverse Event Reporting Description | ||
| Arm/Group Title | Treatment (Nivolumab) | |
| Arm/Group Description | Patients receive 240 mg nivolumab IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease, complete response, or partial response receive 480 mg nivolumab IV over 60 minutes on day 1 of cycle 9. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. | |
All Cause Mortality |
||
| Treatment (Nivolumab) | ||
| Affected / at Risk (%) | # Events | |
| Total | 7/12 (58.3%) | |
Serious Adverse Events |
||
| Treatment (Nivolumab) | ||
| Affected / at Risk (%) | # Events | |
| Total | 5/12 (41.7%) | |
| Cardiac disorders | ||
| Sinus tachycardia | 1/12 (8.3%) | 1 |
| Gastrointestinal disorders | ||
| Jejunal perforation | 1/12 (8.3%) | 1 |
| Pancreatitis | 1/12 (8.3%) | 1 |
| General disorders | ||
| Fatigue | 1/12 (8.3%) | 1 |
| Fever | 2/12 (16.7%) | 2 |
| Infections and infestations | ||
| Infections and infestations - Oth spec | 2/12 (16.7%) | 3 |
| Lung infection | 1/12 (8.3%) | 1 |
| Sepsis | 1/12 (8.3%) | 1 |
| Metabolism and nutrition disorders | ||
| Anorexia | 1/12 (8.3%) | 1 |
| Dehydration | 1/12 (8.3%) | 1 |
| Hypercalcemia | 1/12 (8.3%) | 1 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | ||
| Neoplasms benign, mal, uncpec - Oth spec | 2/12 (16.7%) | 2 |
| Psychiatric disorders | ||
| Delirium | 1/12 (8.3%) | 1 |
| Respiratory, thoracic and mediastinal disorders | ||
| Dyspnea | 3/12 (25%) | 3 |
| Hypoxia | 1/12 (8.3%) | 1 |
| Vascular disorders | ||
| Hypotension | 1/12 (8.3%) | 1 |
Other (Not Including Serious) Adverse Events |
||
| Treatment (Nivolumab) | ||
| Affected / at Risk (%) | # Events | |
| Total | 10/12 (83.3%) | |
| Blood and lymphatic system disorders | ||
| Anemia | 2/12 (16.7%) | 3 |
| Gastrointestinal disorders | ||
| Abdominal pain | 2/12 (16.7%) | 2 |
| Diarrhea | 6/12 (50%) | 12 |
| Nausea | 1/12 (8.3%) | 2 |
| Vomiting | 1/12 (8.3%) | 1 |
| General disorders | ||
| Fatigue | 3/12 (25%) | 4 |
| Fever | 1/12 (8.3%) | 1 |
| Infections and infestations | ||
| Urinary tract infection | 1/12 (8.3%) | 1 |
| Investigations | ||
| Lipase increased | 1/12 (8.3%) | 1 |
| Lymphocyte count decreased | 5/12 (41.7%) | 9 |
| Neutrophil count decreased | 2/12 (16.7%) | 3 |
| Platelet count decreased | 2/12 (16.7%) | 3 |
| Serum amylase increased | 1/12 (8.3%) | 1 |
| White blood cell decreased | 2/12 (16.7%) | 2 |
| Metabolism and nutrition disorders | ||
| Hypercalcemia | 1/12 (8.3%) | 1 |
| Hyperglycemia | 1/12 (8.3%) | 1 |
| Hypocalcemia | 1/12 (8.3%) | 1 |
| Hyponatremia | 1/12 (8.3%) | 2 |
| Musculoskeletal and connective tissue disorders | ||
| Arthralgia | 1/12 (8.3%) | 1 |
| Nervous system disorders | ||
| Headache | 1/12 (8.3%) | 1 |
| Respiratory, thoracic and mediastinal disorders | ||
| Dyspnea | 5/12 (41.7%) | 10 |
| Skin and subcutaneous tissue disorders | ||
| Pruritus | 1/12 (8.3%) | 3 |
| Rash acneiform | 2/12 (16.7%) | 3 |
| Rash maculo-papular | 6/12 (50%) | 16 |
Limitations/Caveats
More Information
Certain Agreements
All Principal Investigators ARE employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Stephen M Ansell MD PhD |
|---|---|
| Organization | Mayo Clinic |
| Phone | 507/284-2511 |
| ansell.stephen@mayo.edu |
- MC1681
- NCI-2017-00307
- MC1681
- P30CA015083